SCHEMBL734543

SCHEMBL734543

COC(=O)C(CC=O)N1CCN(c2ccc(Cl)c(Cl)c2)CCC1=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.52
SMN1; SMN2 Q16637 5/20 0.52
RAB9A P51151 1/20 0.48
HTT P42858 3/20 0.47
MAPK1 P28482 1/20 0.47
TP53 P04637 2/20 0.41
PANK3 Q9H999 1/20 0.41
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
ALDH1A1 P00352 3/20 0.40
RECQL P46063 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
KDM4E B2RXH2 2/20 0.40
THRB P10828 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
POLB P06746 1/20 0.40
LMNA P02545 1/20 0.39
BCL2A1 Q16548 1/20 0.39
CCR1 P32246 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL734542 1.00 MAPT (0.52) MAPTSMN1; SMN2RAB9AHTTMAPK1
SCHEMBL733743 0.88 ALDH1A1 (0.47) MAPTSMN1; SMN2HTTMAPK1MEN1
SCHEMBL733744 0.88 ALDH1A1 (0.47) MAPTSMN1; SMN2HTTMAPK1MEN1
SCHEMBL735610 0.87 MAPT (0.50) MAPTSMN1; SMN2RAB9AHTTMAPK1
SCHEMBL735609 0.87 MAPT (0.50) MAPTSMN1; SMN2RAB9AHTTMAPK1
SCHEMBL734351 0.84 GFER (0.44) MAPTRAB9AHTTMAPK1TP53
SCHEMBL734352 0.84 GFER (0.44) MAPTRAB9AHTTMAPK1TP53
SCHEMBL735368 0.82 ADAMTS5 (0.40) MAPTSMN1; SMN2RAB9AHTTMAPK1
SCHEMBL735367 0.82 ADAMTS5 (0.40) MAPTSMN1; SMN2RAB9AHTTMAPK1
SCHEMBL736074 0.82 LDHA (0.46) MAPTSMN1; SMN2HTTTP53MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138175-B2 Heterocyclyl compounds HOFFMANN-LA ROCHE INC. (US) 2012-03-20 US disclosed
EP-2321285-A1 DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. Hoffmann-La Roche AG (CH) 2011-05-18 EP disclosed
WO-2010012619-A1 DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2010-02-04 WO disclosed
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS CCR2, CCR3, CCR5 MAPT 4751/4885SMN1; SMN2 4455/4885RAB9A 762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.